Method for the diagnosis or prognosis, in vitro, of lung cancer
The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of lung cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, a method for use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.
1. A method for detecting at least one RNA transcript, comprising:
obtaining a biological sample that is collected from a human patient suspected of having lung cancer; and
detecting, in the biological sample, the presence or absence of at least two RNA transcripts comprising a first RNA transcript expressed by a first nucleic acid sequence having at least 99% identity with SEQ ID NO: 4, and a second RNA transcript expressed by a second nucleic acid sequence having at least 99% identity with SEQ ID NO: 6.
2. The method as claimed in claim 1 , wherein the at least two RNA transcripts are mRNA transcripts.
3. The method as claimed in claim 1 , wherein the at least two RNA transcripts are detected by hybridization, amplification, or sequencing.
4. The method as claimed in claim 2 , wherein the mRNA transcripts are detected by bringing the mRNA transcripts into contact with a probe and/or a primer, and detecting the presence or absence of hybridization to the mRNA transcripts.
5. The method as claimed in claim 2 , wherein the mRNA transcripts are detected by detecting the presence or absence of cDNAs obtained from the mRNA transcript transcripts.
6. A method for detecting at least two RNA transcripts, comprising:
obtaining a biological sample that is collected from a human patient that has been diagnosed with lung cancer; and
detecting, in the biological sample, the presence or absence of at least two RNA transcripts comprising a first RNA transcript expressed by a first nucleic acid sequence having at least 99% identity with SEQ ID NO:4, and a second RNA transcript expressed by a second nucleic acid sequence having at least 99% identity with SEQ ID NO: 6.
7. The method as claimed in claim 1 , further comprising detecting, in the biological sample, the presence or absence of a further RNA transcript expressed by a further nucleic acid sequence having at least 99% identity with SEQ ID NO: 2, 3, 8, 11, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, or 242.
8. The method as claimed in claim 1 , further comprising detecting, in the biological sample, the presence or absence of a third RNA transcript expressed by a third nucleic acid sequence having at least 99% identity with SEQ ID NO: 1, 5, 7, or 50.
9. The method as claimed in claim 8 , wherein the third nucleic acid sequence has at least 99% identity with SEQ ID NO: 5 or SEQ ID NO: 7.
10. The method according to claim 5 , wherein the presence or absence of the cDNAs are detected by bringing the cDNAs into contact with a probe and/or a primer, and detecting the presence or absence of hybridization to the cDNAs.
11. The method as claimed in claim 1 , wherein the first nucleic acid sequence is SEQ ID NO: 4, and the second nucleic acid sequence is SEQ ID NO: 6.
12. The method as claimed in claim 11 , wherein the at least two RNA transcripts are mRNA transcripts, and
the mRNA transcripts are detected by detecting the presence or absence of cDNAs obtained from the mRNA transcripts.
13. The method as claimed in claim 11 , further comprising determining an expression level of the at least two RNA transcripts in the biological sample.
14. The method as claimed in claim 1 , further comprising determining an expression level of the at least two RNA transcripts in the biological sample.
15. A method for detecting at least two RNA transcripts, comprising:
obtaining a biological sample that is collected from a human patient suspected of having lung cancer; and
detecting, in the biological sample, the presence or absence of a first RNA transcript expressed by a first nucleic acid sequence having at least 99% identity with SEQ ID NO: 4 by contacting the first RNA transcript or cDNA obtained therefrom with a probe or primers to respectively hybridize to or amplify a region within the first RNA transcript or cDNA obtained therefrom that is defined by a distinct region within the first nucleic acid sequence; and
detecting, in the biological sample, the presence or absence of a second RNA transcript expressed by a second nucleic acid sequence having at least 99% identity with SEQ ID NO: 6 by contacting the second RNA transcript or cDNA obtained therefrom with a second probe or primers to respectively hybridize to or amplify a region within the second RNA transcript or cDNA obtained therefrom that is defined by a distinct region within the second nucleic acid sequence.
16. The method as claimed in claim 1 , wherein no more than 242 specific binding partners are used to detect the at least two RNA transcripts.